You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Highly-sensitive, rapid and low cost plasmonic assay platform for Lyme disease diagnosis

    SBC: CIENCIA INC            Topic: NIAID

    Project Summary/Abstract Lyme disease (LD) is the most common vector-borne illness in the United States and represents a considerable diagnostic challenge. 1-3 The current benchmark for LD diagnosis is the standard two-tiered test (STTT), although the modified two-tier test (MTTT) is rapidly becoming an acceptable alternative. 6 These assays are highly specific but have poor sensitivity, especiall ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  2. A novel clot containing system for improved neurothrombectomy outcomes

    SBC: XTRACT MEDICAL INC            Topic: 106

    PROJECT SUMMARY Mechanical thrombectomy (MT) has recently gained impetus as a treatment for acute ischemic stroke (AIS). Although technical progress has been made, the efficacy of the current techniques remains sub-optimal and MT is still associated with significant complications. Current MT techniques, using stent retrievers or aspiration catheters, achieve successful revascularization after the ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  3. Development of a Multifunctional Rehabilitation Standing and Stepping Device for Persons with Parkinson's Disease

    SBC: TULIP MAKE ME MOVE DESK LLC            Topic: NINDS

    ABSTRACT Tulip Make Me Move Desk, LLC is a startup medical device company based on Randamp;D of the Multifunctional Rehabilitation Standing andamp; Stepping Device (MRSSD) prototype. The MRSSD is a standing desk with a multidirectional moving tabletop that induces stepping movements while standing and simultaneously performing motor and cognitive activities behind it. The MRSSD can serve as a stan ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  4. Development of Broad-Spectrum CyclicAmphiphilic Peptides against Multidrug-Resistant Bacteria

    SBC: AJK BIOPHARMACEUTICAL LLC            Topic: NIAID

    ABSTRACT The emergence of antibacterial resistance to common frontline antibiotics, such as methicillin, vancomycin, cephalosporins, and carbapenem, have created a global public health challenge for millions of patients. It is therefore critical to discover and commercialize new antimicrobial agents that can successfully neutralize multidrug-resistant bacteria (MDRB) with minimal toxicity. The obj ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  5. Development of protease activity-based detector substrates for diagnosing Candida infections

    SBC: BIOSYNESIS, INC.            Topic: NIAID

    Project Summary/Abstract Members of the Candida genus of fungi form part of the normal human microbiota but are also opportunistic pathogens capable of causing serious mucosal and systemic infections. Candida cells grow and divide in suspension (planktonic) cultures, but they also form resilient and drug resistant biofilms – organized, tightly- packed communities of cells that attach to surfaces ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  6. An automated system to differentiate Kawasaki disease from febrile illness with real life clinical datasets in New York City

    SBC: HBI SOLUTIONS INC.            Topic: 100

    ABSTRACT – Kawasaki disease (KD) is the most common cause of acquired heart disease in children. Treatment with intravenous immunoglobulin (IVIG) reduces the incidence of coronary aneurysms and risk of long-term cardiovascular complications. IVIG is recommended to be given within 10 days of illness; however only 4.7% receive the correct diagnosis at the first medical visit. Timely and accurately ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  7. Developing generalized engineering tools to create enhanced phage therapy for the clinic and commercialization

    SBC: FELIX BIOTECHNOLOGY INC            Topic: NIAID

    ABSTRACT Antibiotic-resistant infections are a major public health threat in the U.S. and globally, with Pseudomonas aeruginosa (Pa) being one of the top pathogens of concern. Phage therapy is a promising approach to treat these infections, with benefits of species-targeted activity that spares the host microbiome, an ability to penetrate biofilms and kill metabolically-inactive persister cells, a ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  8. Development of lysosome targeted therapeutics

    SBC: MAJESTIC THERAPEUTICS, LLC            Topic: 102

    Project Summary/Abstract Lysosomal proteolysis facilitates the turnover of organelles and selected long-lived proteins and is a critical regulator of cellular homeostasis. Its aberrant activation promotes drug resistance and cancer progression by generating alternative sources of survival sustaining metabolic fuel to cells that are stressed by hypoxia, radiation, chemotherapy, and targeted agents. ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  9. Development of novel, targeted small molecule inhibitors of DNA repair in high unmet need tumors-TNBC

    SBC: DNATWO, Inc.            Topic: NCI

    DNATWO, Inc. was founded out of Caltech to develop small molecule drugs targeting a new cancer target, DNA2, to treat triple-negative breast cancer (TNBC). We have spent decades unraveling the role of the DNA2 ATP-motor driven nuclease activity in relieving replication stress at the replication fork and carrying out repair at forks collapsed to double strand breaks (DSBs). Our scientific premise i ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  10. Targeting a non-opioid signaling pathway to reverse opioid-induced respiratory depression

    SBC: Olfa Thera, Inc.            Topic: NIDA

    Project Summary/AbstractThe opioid epidemic is a growing public health crisis with dramatic increase in overdose deaths caused by potent opioids like fentanyl. Currently, the standard treatment for opioid-induced respiratory depression is naloxone, a µ-opioid receptor antagonist. However, naloxone is less effective against potent synthetic opioids like fentanyl and induces withdrawal in chronic o ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government